JP2024500945A5 - - Google Patents
Info
- Publication number
- JP2024500945A5 JP2024500945A5 JP2023538766A JP2023538766A JP2024500945A5 JP 2024500945 A5 JP2024500945 A5 JP 2024500945A5 JP 2023538766 A JP2023538766 A JP 2023538766A JP 2023538766 A JP2023538766 A JP 2023538766A JP 2024500945 A5 JP2024500945 A5 JP 2024500945A5
- Authority
- JP
- Japan
- Prior art keywords
- immunotherapy
- protein
- fcγriib
- lower hinge
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020904823 | 2020-10-22 | ||
| AU2020904823A AU2020904823A0 (en) | 2020-12-23 | Modified immunoglobulin and method of use thereof (1) | |
| PCT/AU2021/051548 WO2022133543A1 (en) | 2020-12-23 | 2021-12-22 | Modified immunoglobulin with affinity for fcgammariib and method of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500945A JP2024500945A (ja) | 2024-01-10 |
| JP2024500945A5 true JP2024500945A5 (cg-RX-API-DMAC7.html) | 2025-01-06 |
Family
ID=82156888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538766A Pending JP2024500945A (ja) | 2020-12-23 | 2021-12-22 | ＦｃガンマＲＩＩｂに対する親和性を有する修飾免疫グロブリン及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240018269A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4267627A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024500945A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021408091A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022133543A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250122541A (ko) | 2022-10-25 | 2025-08-13 | 사이즈믹 테라퓨틱, 인코포레이티드. | 변이체 IgG FC 폴리펩티드 및 그 용도 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180360981A1 (en) * | 2003-09-26 | 2018-12-20 | Xencor, Inc. | Novel immunoglobulin variants |
| EP2176298B1 (en) * | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| WO2017214452A1 (en) * | 2016-06-08 | 2017-12-14 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| CN113603780B (zh) * | 2017-03-28 | 2022-07-01 | 礼进生物医药科技（上海）有限公司 | 用于增强肿瘤微环境中免疫应答的治疗剂和方法 |
| JP7626698B2 (ja) * | 2018-09-28 | 2025-02-04 | リビジェン バイオファーマ ホールディングス リミテッド | 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途 |
| WO2020069382A1 (en) * | 2018-09-28 | 2020-04-02 | Lyvgen Biopharma Co., Ltd. | Anti-cd137 binding molecules having engineered fc domains and therapeutic uses thereof |
| CN116368154A (zh) * | 2020-10-08 | 2023-06-30 | 阿菲姆德股份有限公司 | 三特异性结合剂 |
-
2021
- 2021-12-22 JP JP2023538766A patent/JP2024500945A/ja active Pending
- 2021-12-22 EP EP21908155.1A patent/EP4267627A4/en not_active Withdrawn
- 2021-12-22 WO PCT/AU2021/051548 patent/WO2022133543A1/en not_active Ceased
- 2021-12-22 AU AU2021408091A patent/AU2021408091A1/en not_active Abandoned
-
2023
- 2023-06-23 US US18/213,344 patent/US20240018269A1/en active Pending